microRNA Market Size to Increase by USD 6.11 Billion by 2034

microRNA Market Size, Shares and Recent Developments

The global microRNA market was estimated at US$ 1.61 billion in 2023 and is projected to grow to US$ 6.11 billion by 2034, rising at a compound annual growth rate (CAGR) of 12.89% from 2024 to 2034. The increasing prevalence of chronic conditions is driving the market’s growth.

Unlock Infinite Advantages: Subscribe to Annual Membership

Major Key Insights of the microRNA Market

• North America dominated the market share by 41.6% in 2023.
• By region, Asia Pacific is expected to grow at the fastest rate during the forecast period.
• By products & services, the service segment held the largest share of the microRNA market in 2023.
• By application, the cancer segment dominated the market in 2023.
• By application, the infectious diseases segment is anticipated to grow at the fastest rate during the forecast period.
• By end-use, the biotechnology & pharmaceutical companies segment dominated the market in 2023.

microRNA Market: Diagnostics

The term "microRNA market" refers to the dynamic and quickly growing area of the biotechnology and life sciences industries that is focused on the discovery, creation, and promotion of goods and technologies based on microRNA. MicroRNAs are short, non-coding RNA molecules that are extremely conserved and have a role in controlling the expression of certain genes. miRNA is primarily involved in the control of genes. Numerous illnesses can be treated by using miRNA as targets or instruments. miRNA controls a large number of genes involved in DNA repair. In addition to identifying the diagnostic, prognostic, and/or predictive value of individual microRNAs or microRNA signatures as potential biomarkers for patient management, this enormously large body of research has produced innovative technological advancements for the detection of microRNAs in tissue and bodily fluids.

How can AI Improve the microRNA Market?

Advances in biomedical informatics' machine learning field have made it possible to investigate medications that target miRNA, therefore advancing the field of miRNA therapies. Additionally, the outcomes of machine learning models' predictions might be contrasted with miRNA-disease/drug connections that have been confirmed by experimental means. The lack of data available for building trustworthy prediction models may be addressed by machine learning techniques like active learning. Machine learning fairness is a recently developed subject that aims to investigate the impact of model and data biases, such as gender, ethnicity, and disability, on the prediction performance of miRNA treatment.

For instance,

• In July 2023, researchers used AI and microRNA to create a multiclass cancer detection tool. Interest in examining miRNA expression profile data as a potentially less intrusive diagnostic tool for early detection has increased as a result of the correlation between miRNAs and the development of cancer. Utilizing machine learning techniques, new miRNA biomarkers for clinical research have been found, and high-performance pan-cancer classification models have been created.

Top Companies in the microRNA Market

• Thermo Fisher Scientific, Inc.
• DiamiR Biosciences
• New England Biolabs
• NanoString Technologies, Inc.
• Sanofi
• miRecule
• Alnylam
• BioGenex
• Merck KGaA
• LGC Limited
• Takara Bio, Inc.
• Horizon Discovery Group plc.
• QIAGEN
• GeneCopoeia, Inc.

Pipeline of DiamiR in the microRNA Market

Innovation by MiRecule in the microRNA Market

Increasing Number of Clinical Trials Drive the microRNA Market

Because miRNAs can be used as therapeutic targets in clinical settings, research on them has been concentrated. Numerous clinical trials employing miRNAs for medication testing, diagnosis, and screening are now in progress. Biopharmaceutical firms are becoming more involved in this dynamic sector, and current clinical studies suggest that anti-miR and miR-mimic medicines represent a new class of compounds with potential therapeutic uses in the future. Clinical trials for nearly all human disorders are focusing on the therapeutic potential of miRNA therapies.

For instance,

• The Clinical Trials Database was consulted on January 20, 2023, and a search for "microRNA" produced 1213 results. These results comprised 414 finished studies, 91 continuing studies, and 368 studies that were either in the recruitment or not-yet-recruited phase.

Safety & Efficiency Issues Restraint the microRNA Market

It is still difficult to determine the efficacy and safety of miRNA-based therapies, particularly those that aim to target human tissues via the administration of miRNA mimics or antagomirs. MiRNA delivery techniques have some disadvantages, including a weak binding affinity for complementary sequences, fast clearance from blood, toxicity that occurs off-target, vulnerability to nucleases upon introduction into biological systems, and off-target toxicity. Moreover, they may induce involuntary gene silencing because they target many pathways through imprecise matching in the 3′ UTR region.

microRNA Therapeutics is the future of the microRNA Market

These short RNAs offer themselves for therapeutic reasons toward a focused alteration of cell processes that are critical to a disease phenotype, in addition to the diagnostic potential of changed miRNA expression levels. Understanding the functions of miRNAs in development and illness, especially cancer, has made miRNAs desirable targets and instruments for cutting-edge treatment strategies. Numerous treatments targeting miRNA have advanced to the clinical stage. Consequently, substantial expenditures have been made in the development of miRNA-based therapeutics by multidisciplinary sectors spanning biology, chemistry, and medical research.

The Service Segment Dominated in 2023

By products & services, the service segment held the largest share of the microRNA market in 2023. There are different types of services associated with microRNA. Each service has different roles. Quantification of customer-provided total RNA or microRNA samples is included in the microRNA sequencing services, which also comprise microRNA library creation, cluster production, and sequencing. From sample extraction to data processing, CD Genomics' microRNA sequencing service provides complete and integrated services. Quality control for sample extraction, sequencing, library preparation, bioinformatics analysis, and data reporting are all included in the service.

The Cancer Segment Held the Largest Share

By application, the cancer segment dominated the microRNA market in 2023. Nowadays, cancer is one of the major issues. Researchers are always looking for novel elements that contribute to the carcinogenesis process. miRNAs are thought to be possible cancer indicators. First, because miRNA molecules are found in a variety of bodily fluids, they are easily accessible for research. Second, miRNAs' great biological stability makes it easier to discover them. Third, miRNAs exhibit tissue-specific expression in many situations and control all phases of tumor formation.

For instance,

• In June 2024, molecular diagnostic startup Craif, which created an early cancer detection platform based on miRNA, is pleased to announce that it was chosen as one of the 65 firms that were admitted into the world's biggest medical technology accelerator, the 2024 Medtech Innovator Accelerator Cohort. Craif was selected from a global pool of over 1,300 enterprises.

Fastest Growing: The Infectious Diseases Segment

By application, the infectious diseases segment is anticipated to grow at the fastest rate in the microRNA market during the forecast period. Because extracellular miRNAs can be extracted from bodily fluids, they are excellent biomarker candidates. Ex-miRNAs in patient samples might be quantified using RT-PCR, which is currently often utilized in the clinical environment to rapidly detect infections (e.g., respiratory infections in newborns with bronchiolitis). According to a number of recent research, miRNAs have a critical role in controlling immune cell differentiation, maturation, and activation, which in turn affects how the host immune system responds to infection. miRNAs have been investigated recently in a variety of infectious illnesses as therapeutic targets and diagnostic indicators.

The Biotechnology & Pharmaceutical Companies Segment Dominated

By end-use, the biotechnology & pharmaceutical companies segment dominated the microRNA market in 2023. The main function of microRNA is in therapeutics and various sequencing-associated activities. Both biotechnology and pharmaceutical companies are highly invested in the development of new therapeutics and understanding the function of genes. As the population grows, unhealthy lifestyles and environmental conditions contribute to chronic conditions, pharma, and biotech companies are conducting clinical trials and research studies. Companies are heavily investing and collaborating with other companies and government institutions to come up with better solutions.

For instance,

• In March 2023, The University of Leipzig in Germany and the RNA delivery and therapeutics business SiSaf Ltd. will work together to create tailored micro-interfering RNAs (miRNA) for the treatment of cancer, with a primary focus on pancreatic cancer. In the lab of Achim Aigner, SiSaf will create formulations of miRNA Bio-Courier that will be tested in pancreatic cancer models. As per the agreement, SiSaf is the only party that has the ability to purchase a worldwide license for a patent held by the institution.

Growing Organization’s Contribution Drive North America

North America dominated the microRNA market share by 41.6% in 2023. because there is a robust biotechnology and pharmaceutical sector, a well-established healthcare infrastructure, and large expenditures in research and development. Numerous industry participants and university research centers actively involved in miRNA research are based in the region. The availability of cutting-edge technology, collaborative efforts between academia and business, and supportive government initiatives all contribute to North America's commercial supremacy in the microRNA market.

For instance,

• In July 2023, The United States-based DiamiR Biosciences and JADBio reached an agreement for the use of the latter's Automated Machine Learning (AutoML) Platform and Services to create predictive models based on DiamiR's microRNA panels and other variables for Rett syndrome and Alzheimer's disease risk assessment. DiamiR Biosciences is a company that develops novel, non-invasive blood-based diagnostic tests for brain health and other diseases.

Rise in microRNA Therapeutics Promote Asia Pacific’s Growth

By region, Asia Pacific is expected to grow at the fastest rate during the forecast period. Some of the factors propelling the microRNA market expansion in the area include the rapidly expanding population, an increase in the prevalence of cardiovascular illnesses, a greater demand for microRNA-based treatments, and a stronger focus on research and development initiatives.

For instance,

• In 2022, MiRXES, a Singaporean company, announced that it would collaborate with the National Heart Centre and National University Heart Centres in Singapore to manage pulmonary hypertension. Thanks to the collaboration, the first multi-center study employing early detection microRNA biomarkers in Southeast Asia has begun. The institute wants to use microRNA biomarkers to identify pulmonary hypertension at an early stage.

China has been a popular complementary and alternative medicine for the treatment of cancer in recent decades. MicroRNAs, or miRNAs, have been intensively studied for their potential to target miRNAs and play essential roles in several pathological processes, including cancer. Additionally, Chinese medicinal herbs have been proven to have anti-cancer properties through miRNA targeting. Drawn from the root of Coptis chinensis, berberine is a well-known herbal remedy with anti-cancer properties.

Recent Developments in the microRNA Market

• In July 2024, adult mice with a particular kind of hereditary hearing loss have had their hearing restored by researchers using gene editing. They demonstrated that the animal's ability to hear was restored by blocking a defective copy of a gene known as a microRNA (miRNA). The method used by a National Institutes of Health (NIH))-supported research team, published in Science Translational Medicine, may potentially result in hereditary hearing loss remedies for humans.
• In February 2024, the FDA in the United States gave the go-ahead for ARTHEx Biotech S.L. to begin the Phase I-IIa ArthemiRTM study of ATX-01 for the treatment of Myotonic Dystrophy Type 1 (DM1). ARTHEx Biotech S.L. is a clinical-stage biotechnology company focused on developing novel medicines through the modulation of microRNAs.
• In September 2023, Researchers at Purdue University created a novel cancer treatment that targets tumors by deceiving cancer cells into ingesting a little piece of microRNA that normally prevents cell proliferation. According to a paper published in Oncogene on Monday, September 4, during a 21-day trial, tumors treated with the novel therapy did not grow in size, but tumors that were left untreated tripled in size during the same timeframe.

Segments Covered in the Report

By Products & Services

• Services
  • Type
    • Isolation & Purification
    • miRNA cDNA Synthesis
    • Profiling, Localization, & Quantification
    • Functional Analysis
    • Others
  • Specimen
    • Whole Blood
    • Serum
    • Plasma
    • FFPE
    • Fresh Frozen Tissue
    • Others
• Products
  • Instruments
    • Technology
      • Real-Time PCR
      • Microarray
      • NGS
      • Others
    • Workflow
      • Isolation & Purification
      • miRNA cDNA Synthesis
      • Profiling, Localization, & Quantification
      • Functional Analysis & Others
      • Others
  • Consumables
    • Specimen
      • Workflow
      • Isolation & Purification
      • miRNA cDNA Synthesis
      • Profiling, Localization, & Quantification
      • Functional Analysis & Others
      • Others
    • Whole Blood
      • Serum
      • Plasma
      • FFPE
      • Fresh Frozen Tissue
      • Others

By Application

• Cancer
• Infectious Diseases
• Immunological Disorder
• Cardiovascular Disease
• Neurological Disease
• Others

By End-use

• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Others

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailands
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait